Alternative metrics for assessing clinical benefit with immunotherapy in oncology

Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma.

(2017) M. A. Marshall et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment

(2016) Mizuki Nishino   Journal for ImmunoTherapy of Cancer

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

(2015) Peter Johnson et al.   Biomed Research International

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma

(2014) David McDermott et al.   CANCER TREATMENT REVIEWS

Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

(2014) S. J. Antonia et al.   CLINICAL CANCER RESEARCH

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

(2014) Henrik Hjorth-Hansen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

What have we learned from cancer immunotherapy in the last 3 years?

(2014) Paolo A Ascierto et al.   Journal of Translational Medicine

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

(2013) F Joulain et al.   BRITISH JOURNAL OF CANCER

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Statistical issues and challenges in immuno-oncology

(2013) Tai-Tsang Chen   Journal for ImmunoTherapy of Cancer

Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

(2012) James E. Signorovitch et al.   VALUE IN HEALTH

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH